Showing results (291-300 of 346) with videos related to
Sort By:
Pageof 35
European Journal of Cancer & Clinical Oncology|July 1, 1984
A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphomaW P Steward, I D Todd, M Harris, et al.British Journal of Cancer|December 1, 1987
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancerM H Bronchud, J H Scarffe, N Thatcher, et al.Anticancer Research|May 1, 1997
Treatment of lymphoid cell malignancy with In-114m labelled autologous lymphocytesH L Sharma, R A Cowan, B Murby, et al.Hematological Oncology|July 1, 1987
VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignanciesH Anderson, J H Scarffe, M Lambert, et al.British Journal of Cancer|May 14, 1998
Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra costS M Lee, J A Radford, L Dobson, et al.British Medical Journal|July 4, 1970
Combination chemotherapy in generalized Hodgkin's diseaseW M Nicholson, M E Beard, D Crowther, et al.Cancer Chemotherapy and Pharmacology|January 1, 1985
In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma cameraS E Owens, N Thatcher, H Sharma, et al.Lancet (London, England)|March 17, 1984
Steroid-hormone receptors and survival after first relapse in breast cancerA Howell, D M Barnes, R N Harland, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyM Van Glabbeke, A T van Oosterom, J W Oosterhuis, et al.British Journal of Cancer|December 23, 1998
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma groupO S Nielsen, P Dombernowsky, H Mouridsen, et al.Pageof 35